查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854493

鞘内帮浦市场按帮浦类型、药物类型、治疗领域和最终用户划分 - 全球预测 2025-2032

Intrathecal Pumps Market by Pump Type, Drug Type, Therapy Area, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，鞘内泵市场规模将达到 9.9161 亿美元，复合年增长率为 9.06%。

关键市场统计数据
基准年2024年 4.9522亿美元
预计年份：2025年 5.4067亿美元
预测年份 2032 9.9161亿美元
复合年增长率 (%) 9.06%

本书权威地介绍了鞘内泵疗法的发展历程、临床重点、监管预期以及决定其应用的相关人员。

鞘内泵疗法已从一种小众临床干预手段发展成为全身性治疗无效或产生难以接受的副作用时，治疗复杂疼痛和痉挛的核心手段。在过去十年间，临床医生拓展了适应症范围并优化了患者选择，而工程师则提高了设备的可靠性、药物传输的精确度和可程式设计。因此，鞘内泵生态系统如今涵盖了众多利益相关者，包括植入医生、设备相关人员、医院采购团队、门诊中心、支付方以及寻求持久症状控制并降低全身风险的患者。

先进输注演算法和整合远端监测的引入，正将争论的焦点从是否进行鞘内注射转移到如何优化长期门诊治疗。同时，监管机构日益关注上市后监测以及人机互动风险，促使製造商加强对临床证据和生命週期管理的投入。总而言之，这些发展给临床领导者和商业策略家带来了挑战，他们需要在一个更为复杂的环境中应对，在这个环境中，决定产品应用轨蹟的不再仅仅是产品的新颖性，而是安全性、疗效、服务和成本效益。

本执行摘要总结了目前影响鞘内帮浦治疗的临床、商业和政策动态。它阐述了影响相关人员决策的转型框架，重点介绍了关税主导的供应链在2025年之前的影响，并提取了相关人员需要考虑的细分市场、区域和竞争考察。其目标是为高阶主管和临床领导者提供一个连贯且可操作的基础，以便将产品开发、市场推广和业务策略与不断变化的患者和系统需求相协调。

技术创新在设备工程、远端监测、临床实践和监管预期等方面的融合，正在重塑医疗技术的应用路径和医疗服务模式。

鞘内帮浦领域正受到技术、临床实务和医疗服务模式等多面向因素的共同影响而改变。设备层面的创新优先考虑设备的使用寿命和精准度，而电池和导管介面的改进则旨在降低再次手术率并提高患者的便利性。同时，远端监测和数位遥测技术的整合使得设备相关併发症的早期发现和剂量调整的快速进行成为可能，从而影响后续的治疗流程和临床资源的分配。

临床实践正从独立的门诊计画转向混合监测模式，该模式结合了定期面对面评估和数据驱动的远端调整。这种转变正在改变传统的以医院为中心的转诊模式，并支持门诊手术中心在移植和追踪方面的广泛应用。同时，对鸦片类药物管理的日益重视以及鞘内注射Baclofen治疗痉挛的证据不断增加，引发了关于患者选择标准和长期管理路径的讨论。这种临床转变对实证医学的产生、病人教育和跨学科护理协调提出了新的要求。

监管和报销环境也在不断演变。监管机构优先考虑对器械-药物组合产品进行强有力的上市后监测和清晰的标籤标註，要求製造商证明其生命週期安全性。支付者则更密切地关注长期价值提案，不仅关注急性手术成本，还关注诸如减少全身用药、住院次数和减轻看护者负担等结果。因此，商业策略越来越重视真实世界证据的收集、基于价值的合约试点以及与医疗系统的伙伴关係，以展示能够同时支持临床结果和经济目标的整合式医疗路径。

总而言之，这些变革性转变不仅重塑了产品蓝图，也重塑了鞘内疗法规模化所需的营运和商业架构。能够有效推动变革的相关人员，应将设备性能与医疗服务创新和循证实践相结合，从而降低推广门槛，并确保与医疗服务提供者和支付方建立长期的治疗伙伴关係。

重点阐述了2025年关税调整如何迫使供应链、筹资策略和设计快速调整，以保障临床服务的连续性和利润率。

2025年的贸易政策变化和关税调整为鞘内泵供应链和筹资策略引入了新的变数。部分医疗设备组件和进口次组件的关税上调，增加了依赖地理分散生产网路的製造商的投入成本。为因应此变化，各公司加快了供应商多元化策略，重新评估了其采购布局，并优先与那些在前置作业时间和价格方面提供更高透明度和灵活性的供应商签订合约。除了这些供应方面的应对措施外，各公司还进行了营运方面的调整，例如增加关键导管和电子组件的库存缓衝，以及实施更严格的零件认证流程。

临床医师和医院采购团队观察到，前置作业时间间歇性延长以及紧急病例的优先分配更为频繁，都对后续流程产生了影响。由于短期供应商难以承受关税相关的成本压力，门诊手术中心更重视库存管理。同时，一些製造商实施了有针对性的价格调整和服务合约修订，以抵消不断上涨的投入成本，同时保障高风险患者获得必要的治疗方法。

围绕关税永久性的政策不确定性促使企业进行了一些策略调整，这些调整可能会持续到2025年以后。製造商加大了近岸外包和本地化力度，以减轻跨境关税的影响，而製造外包则在低关税地区扩大了产能。此外，企业越来越关注供应链弹性设计，即透过零件的标准化和模组化来减少对单一来源、受关税影响的零件的依赖。这些调整提高了中期供应的连续性，但也需要资本投资和跨部门协调，从而影响了短期利润率和产品上市时间表。

对医疗保健产业的领导者而言，2025 年关税环境带来的启示是，供应链韧性如今已成为临床连续性规划的策略要素。采购团队和医疗设备申办方正日益加强在紧急应变计画方面的合作，包括双源采购策略和上游供应商风险的可视性。由于关税波动仍是规划中需要考虑的因素，那些在其营运模式中融入灵活采购、缓衝策略和积极供应商沟通的机构，将更有利于维持治疗药物的供应并保障患者的诊疗路径。

全面的细分洞察揭示了设备类型、药物选择、治疗适应症和护理环境如何相互作用，从而决定临床工作流程和商业化策略。

要了解治疗效果和商业化路径，需要深入了解构成鞘内帮浦市场的产品和临床细分。根据泵的类型，治疗方法方案涵盖了用于短期或住院治疗的体外佩戴式输注系统，以及用于慢性、长期鞘内治疗的植入式泵，每种泵在易用性、感染控制和维护方面都有其独特的考虑。这些设备类别会影响临床医师的工作流程，也会影响治疗地点。植入式系统通常需要专门的手术环境和长期追踪基础设施，而体外设备通常适用于急性期或过渡期治疗。

药物製剂和相容性直接影响临床方案和标籤。根据药物类型，鞘内治疗包括使用Baclofen（用于标靶控制痉挛）、局部麻醉剂（用于局部镇痛）以及鸦片类药物（用于难治性癌症和严重慢性疼痛）。每类药物都有其独特的耐受性、给药方式和监测要求，因此临床医生需要根据具体情况调整装置程序和追踪频率，以降低导管相关性肉芽肿和全身性副作用等风险。因此，鞘内药物的选择与药理学、装置选择和病人咨询密切相关。

治疗应用进一步完善了护理路径。根据治疗领域，鞘内介入治疗可应用于疼痛管理和痉挛管理。疼痛管理本身又分为癌症疼痛和慢性非癌症疼痛，不同族群在植入选择、鸦片类药物管理实务和安宁疗护整合方面有显着差异。痉挛管理涵盖脑性麻痹、多发性硬化症和脊髓损伤等疾病，每种疾病都有其独特的功能目标、多学科照护需求和长期復健意义。针对这些临床亚人群客製化设备功能和服务模式，可以提高患者的依从性和功能预后。

终端用户动态同样会影响部署和服务模式。基于终端使用者的采用途径包括门诊手术中心、医院和专科诊所，它们各自拥有不同的营运能力、报销环境和人员配备模式。由于效率高且符合病患偏好，门诊手术中心越来越倾向于进行择期植入手术，而医院通常需要处理病情更为复杂的病例和更高的手术全期风险。提供长期设备程式设计和多学科追踪的专科诊所对于维持治疗效果和收集结果数据至关重要。了解这些细分视角之间的交集对于设计符合医疗服务实际情况的市场推广策略、临床医生教育计画和长期服务方案至关重要。

关键区域洞察阐述了美洲、欧洲、中东和非洲以及亚太地区的监管、报销和基础设施现状将如何影响科技的采纳和普及策略。

区域动态影响鞘内帮浦的临床应用、监管环境和供应链设计。在美洲，紧密的学术中心和社区医院网路支援早期应用，并进行了完善的核准后临床研究。该地区复杂的医保报销流程和支付方的监管影响申办方对证据生成的优先排序，而一体化的医院系统则支持整合式护理路径，从而促进长期追踪和设备维护。因此，製造商通常会根据医疗系统的证据需求和价值验证试验来制定打入市场策略。

欧洲、中东和非洲的监管和报销环境各不相同，这迫使企业采取灵活的打入市场策略。西方国家通常强调疗效比较和卫生技术评估框架，鼓励製造商投资于真实世界结果和成本效益研究。相较之下，中东和非洲部分地区则优先考虑准入和基础设施建设，这可能为有针对性的能力建设方案和本地伙伴关係创造机会。如果证据和服务支持到位，某些地区的跨境监管协调工作和集中采购机制可以加速技术应用。

亚太地区既有监管体系完善的成熟市场，也有对专业医疗基础设施快速投资的新兴市场。在该地区已开发国家，临床创新者和私人医疗系统推动了对高效能医疗器材和综合服务模式的需求。而在新兴市场，需求往往受到手术能力投资、疾病负担变化以及地区报销政策的影响。寻求区域规模的开发商通常采用混合策略，将成熟市场的直接布局与新兴市场的经销商伙伴关係及培训计画相结合，以确保临床应用的成功和医疗服务的连续性。

这些因素包括在本地建立实证基础的必要性、对移植和追踪临床团队进行培训的重要性，以及供应链韧性的价值。根据当地的监管、支付方和基础设施实际情况调整商业性和临床策略，可以加快技术推广应用，同时确保不同医疗保健系统都能获得治疗并发挥其临床疗效。

关键的公司层面洞察揭示了现有企业和创新参与企业如何透过临床证据、服务模式和软体差异化来竞争。

鞘内帮浦市场的竞争格局反映了现有设备的可靠性与针对特定临床需求的专业创新者崛起之间的平衡。现有製造商凭藉长期的临床数据、广泛的服务网络以及降低植入风险并支持后续护理的全面培训项目，保持市场优势。这些优势增强了机构的信心，并简化了医院和专科诊所的采购决策，这些机构的临床团队需要高可靠性和完善的售后支援。

同时，新参与企业和相关医疗技术公司正透过软体赋能功能、远端监控和模组化设计理念来凸显自身优势，这些理念强调易于编程和减少维护。这些产品吸引了注重门诊病人照护模式的医疗系统和寻求更精细剂量调整能力的专家。设备开发商和製药公司之间的合作也在不断增加，尤其是在药物-器械联合治疗策略方面，共同开发可以简化标籤和临床试验设计。

服务和商业模式正日益成为竞争定位的核心。提供全面临床医生培训、现场技术支援以及透明的保固和更换政策的公司，能够增强临床路径的依赖。此外，投资于结果註册和真实世界证据倡议的供应商，能够与支付方和医疗系统建立更强有力的价值主张。与医院、学术中心和復健网络建立策略伙伴关係，透过将设备纳入既定的护理路径，进一步扩大了覆盖范围并促进了产品的采用。

对于采购者和医疗系统领导者而言，供应商的选择不再仅仅取决于设备功能，而是受到更广泛因素的影响。总医疗成本、服务品质、实证实践以及在诊疗路径重塑方面的合作能力都变得同等重要。因此，能够整合临床支援、资讯服务和灵活商业性安排的供应商，更有可能赢得长期伙伴关係，并在复杂的医疗服务系统中推广鞘内治疗。

为医疗器材製造商、临床医生和支付方提供切实可行的建议，以协调实证医学、数位化能力、供应链韧性和商业模式，以实现永续成长。

产业领导者必须采取果断行动，使产品蓝图、临床证据产生和供应链韧性与不断发展的医疗服务模式保持一致。首先，应优先考虑将设备性能与具有临床意义的结果联繫起来的综合价值证明，例如减少全身用药、降低住院率以及改善痉挛患者的功能状态。儘早与支付方和大型医疗系统合作，制定切实可行的证据收集倡议，将有助于缩短报销审批流程，并支持基于价值的合约试点项目。

其次，投资远端监测和远端检测技术，以实现混合追踪模式，并在不影响安全性的前提下减少门诊就诊次数。远端资料流不仅提升了患者的便利性，还能提供实际应用的终点指标，进而增强经济效益。此外，配合临床医生培训项目，使更广泛的外科和专科诊所网路能够采用植入和编程通讯协定，可以将适用的医疗服务扩展到三级医疗中心以外的场所。

第三，制定供应链策略，强调双重采购、尽可能实现在地化生产，并采用以供应为导向的设计方法，减少对受关税影响零件的依赖。策略性库存管理和供应商伙伴关係可以保障净利率，同时因应短期供应中断。此外，还应与復健和安宁疗护机构建立伙伴关係，将鞘内治疗纳入多学科诊疗路径，以提高患者识别率和治疗连续性。

最后，要围绕服务和结果而非硬体销售来建立商业模式。尽可能提供灵活的合约、保固方案和基于结果的附加条款，以使奖励与购买者保持一致。透过将实证实践、数位化能力和稳健营运整合到一套连贯的打入市场策略中，行业领导者将能够更好地扩大治疗方法规模，同时应对支付方的监管和临床医生的期望。

我们采用透明严谨的调查方法，结合临床医生访谈、法规和文献审查、供应链分析以及同行评审检验，以确保获得可操作的洞见。

本调查方法采用多种方法，确保研究结果的严谨性和可重复性。主要研究包括对移植医生、采购负责人和临床专案经理进行结构化访谈，以了解操作流程、病患选择标准和后续工作流程。这些第一手观点，以及由临床医生组成的顾问专题研讨会的意见，检验了临床假设，并突显了在不同医疗机构推广鞘内治疗所面临的实际障碍。

二次研究涵盖了监管文件、同行评审的临床文献和操作最佳实践指南，以收集安全讯号和设备性能主题。分析了产品技术规格和服务模式描述，以发现新兴的设计趋势和供应商能力。此外，还分析了临床註册摘要和已发表的结果研究，以综合分析与Baclofen治疗、局部麻醉剂使用和阿片类药物辅助鞘内注射相关的治疗和安全性叙述。

我们的供应链和政策分析利用关税和贸易出版物、公开的关税表以及采购案例研究，评估了2025年关税变化对营运的影响。我们运用情境分析技术评估了可能的供应方应对措施，包括近岸外包、双重采购和库存策略，以了解其对製造商和医疗保健提供者的影响。研究结果透过跨部门同行评审检验，以确保其具有实际意义和事实准确性。

此研究方法优先考虑透明度和可重复性。资料缺口均已记录，并透过后续访谈和保守的解读予以弥补。这种严谨的调查方法确保了结论基于当前的临床实践、监管现实以及鞘内泵生态系统中相关人员面临的营运限制。

简洁的结论强调了在获取临床价值、确保供应弹性以及使证据与支付方和提供者的需求保持一致方面的关键策略要务。

鞘内帮浦治疗正处于曲折点，临床前景、技术能力和政策动态在此交汇，为相关人员创造了新的机会和责任。设备设计和遥测技术的进步正在推动更安全、以患者为中心的护理模式的发展，而不断变化的支付方期望和监管重点则要求提供更有力的证据和更完善的生命週期管理。 2025年关税上调的经验凸显了分散式供应链的脆弱性，以及製定策略性弹性规划以保障医疗服务连续性的必要性。

按泵类型、药物选择、治疗领域和最终用户偏好进行细分，凸显了产品特性与临床工作流程和支援服务的契合度如何决定产品的成功应用。监管预期和基础设施的区域差异，使得市场需要采取更具针对性的策略。竞争优势日益不仅取决于硬体规格，还取决于服务品质、实证医学证据产生和数位化整合。

展望未来，那些整合可靠的真实世界证据计画、投资远端监测并增强供应链灵活性的相关人员，将更有利于扩大治疗覆盖范围并展现长期价值。製造商、临床网络和支付方之间的合作将加速疗法的推广应用，并确保鞘内疗法能够为患有复杂疼痛和痉挛的患者带来切实有效的治疗效果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • MRI相容型鞘内帮浦的日益普及提高了诊断影像的安全性。
  • 扩展鞘内泵系统中远端患者监护集成，以实现即时治疗调整
  • 越来越重视微创填充和可程式设计药物输送脊髓内泵设计
  • 人们对透过标靶脊椎给药进行鸦片类药物替代镇痛的兴趣日益浓厚
  • 监管部门的核准加速了下一代可充电鞘内泵技术的市场应用
  • 开发用于自动剂量控制和併发症检测的智慧感测器
  • 成本效益和报销压力影响医院对鞘内泵的采用。
  • 新兴市场对鞘内泵疗法的接受度提高，主要得益于伙伴关係和在地化生产。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依泵浦类型分類的鞘内泵浦市场

  • 外置泵
  • 植入式帮浦

9. 依药物类型分類的鞘内帮浦市场

  • Baclofen
  • 局部麻醉剂
  • 阿片类药物

第十章 依治疗领域分類的鞘内帮浦市场

  • 疼痛管理
    • 癌症痛
    • 慢性非癌性疼痛
  • 痉挛管理
    • 脑性麻痹
    • 多发性硬化症
    • 脊髓损伤

第十一章 鞘内帮浦市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

第十二章 鞘内帮浦市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 鞘内帮浦市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国鞘内帮浦市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Medtronic plc
    • Flowonix Medical, Inc.
    • Tricumed Medizintechnik GmbH
    • Teleflex Inc.
    • Johnson & Johnson Services Inc.
Product Code: MRR-205091A8875F

The Intrathecal Pumps Market is projected to grow by USD 991.61 million at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 495.22 million
Estimated Year [2025] USD 540.67 million
Forecast Year [2032] USD 991.61 million
CAGR (%) 9.06%

An authoritative introduction that frames intrathecal pump therapy evolution, clinical priorities, regulatory expectations, and stakeholder decision drivers shaping adoption

Intrathecal pump therapy has matured from a niche clinical intervention to a central tool for managing complex pain and spasticity when systemic therapies fail or cause unacceptable side effects. Over the past decade clinicians have expanded indications and refined patient selection, while technologists have improved device reliability, drug delivery precision, and programmability. As a result, the intrathecal pump ecosystem now intersects diverse stakeholders: implanting physicians, device manufacturers, hospital procurement teams, ambulatory centers, payers, and patients seeking durable symptom control with fewer systemic risks.

The introduction of advanced infusion algorithms and integrated telemetric monitoring has shifted discussions from simply whether to use intrathecal delivery toward how to optimize long-term therapy in outpatient settings. Concurrently, regulatory agencies have sharpened focus on post-market surveillance and device-human interface risks, prompting manufacturers to invest in clinical evidence and lifecycle management. Taken together, these developments demand that clinical leaders and commercial strategists navigate a more complex environment where safety, outcomes, service, and cost-efficiency determine adoption trajectories rather than device novelty alone.

This executive summary synthesizes the clinical, commercial, and policy dynamics shaping intrathecal pump therapy today. It frames the transformational shifts influencing stakeholder decisions, highlights tariff-driven supply chain implications for 2025, and distills segmentation, regional, and competitive insights actors must consider. The goal is to provide a coherent, actionable foundation for executives and clinical leaders to align product development, market access, and operational strategies with evolving patient and system needs.

How converging innovations in device engineering, remote monitoring, clinical practices, and regulatory expectations are reshaping adoption pathways and care delivery models

The intrathecal pump landscape is undergoing transformative shifts driven by converging forces in technology, clinical practice, and healthcare delivery models. Device-level innovation has prioritized longevity and precision; batteries and catheter interfaces have seen incremental improvements that reduce revision rates and improve patient convenience. Simultaneously, the integration of remote monitoring and digital telemetry is enabling earlier detection of device-related complications and more responsive dose titration, which in turn influences follow-up workflows and clinic resource allocation.

Clinical practice is shifting from episodic in-clinic programming to hybrid monitoring models that combine periodic in-person assessments with data-driven remote adjustments. This evolution supports broader use of ambulatory surgical centers for implantation and follow-up, altering traditional hospital-centered referral patterns. At the same time, heightened attention to opioid stewardship and growing evidence for intrathecal baclofen in spasticity care have expanded conversations around patient selection criteria and long-term management pathways. These clinical shifts are creating new expectations for evidence generation, patient education, and multidisciplinary care coordination.

Regulatory and reimbursement environments are also evolving. Agencies are prioritizing robust post-market surveillance and clearer labeling on device-drug combinations, requiring manufacturers to demonstrate lifecycle safety. Payers are scrutinizing long-term value propositions more closely, looking beyond acute procedural costs to outcomes such as reduction in systemic drug use, hospitalization, and caregiver burden. As a result, commercial strategies increasingly emphasize real-world evidence collection, value-based contracting pilots, and partnerships with health systems to demonstrate integrated care pathways that support both clinical outcomes and economic objectives.

Taken together, these transformative shifts are reshaping not just product roadmaps but also the operational and commercial architectures required to scale intrathecal therapies. Effective stakeholders will be those that harmonize device performance with care delivery innovations and evidence generation to lower barriers to adoption and secure long-term therapeutic partnerships with providers and payers.

A focused analysis of how 2025 tariff shifts forced rapid supply chain adaptation, procurement strategies, and design changes to protect clinical continuity and margins

Trade policy changes and tariff adjustments in 2025 introduced a new variable into intrathecal pump supply chains and procurement strategies. Increased duties on select medical device components and imported subassemblies elevated input costs for manufacturers that rely on geographically distributed production networks. In response, organizations accelerated supplier diversification strategies, re-evaluated sourcing footprints, and prioritized supplier contracts that provide greater transparency and flexibility around lead times and pricing. These supply-side responses have been complemented by operational changes such as increased inventory buffers for critical catheter and electronic components and more rigorous component qualification processes.

Clinicians and hospital procurement teams observed the downstream effects through intermittent lead-time extensions and more frequent allocation prioritization for urgent cases. Ambulatory surgical centers reported heightened attention to stock management as shorter-term suppliers struggled to absorb tariff-related cost pressures. In parallel, some manufacturers implemented targeted price adjustments or revised service contracts to offset increased input costs while protecting access to essential therapies for high-acuity patients.

Policy uncertainty surrounding tariff permanence encouraged several strategic pivots that may endure beyond 2025. Manufacturers intensified nearshoring and localization efforts to reduce exposure to cross-border duties, while contract manufacturers expanded capacities in lower-tariff jurisdictions. Additionally, there was accelerated interest in design-for-supply resilience, where component standardization and modularization reduce dependence on single-source, tariff-exposed parts. These adaptations improved medium-term supply continuity but also required capital investment and cross-functional coordination, affecting short-term margins and product rollout timelines.

For healthcare leaders, the lesson from the 2025 tariff environment is that supply chain resilience is now a strategic dimension of clinical continuity planning. Procurement teams and device sponsors increasingly collaborate on contingency planning, including dual-sourcing strategies and visibility into upstream supplier risk. As tariff volatility persists as a planning consideration, organizations that embed flexible sourcing, buffer strategies, and proactive supplier engagement into their operating models will be better positioned to sustain therapy availability and protect patient care pathways.

Comprehensive segmentation insights revealing how device type, drug selection, therapeutic indication, and care setting intersect to determine clinical workflows and commercialization tactics

Understanding outcomes and commercialization pathways requires a granular view of the product and clinical segmentation that structures the intrathecal pump landscape. Based on pump type, the therapeutic continuum spans externally wearable infusion systems intended for short-term or hospital-based use and implantable pumps designed for chronic long-term intrathecal therapy, each presenting distinct usability, infection control, and maintenance considerations. These device categories inform clinician workflows and influence where care is delivered; implantable systems typically demand surgically oriented settings and long-term follow-up infrastructure, whereas external devices often align to acute or transitional care episodes.

Drug formulation and compatibility directly shape clinical protocols and labeling. Based on drug type, intrathecal therapy incorporates agents such as baclofen for targeted spasticity control, local anesthetics that permit regional analgesia, and opioids deployed for refractory cancer and severe chronic pain. Each drug class brings unique tolerance profiles, dosing paradigms, and monitoring requirements, and clinicians calibrate device programming and follow-up frequency to mitigate risks like catheter-related granulomas or systemic adverse effects. The selection of an intrathecal agent therefore tightly couples pharmacology with device selection and patient counseling.

Therapeutic application further refines care pathways. Based on therapy area, intrathecal interventions serve pain management and spasticity management domains. Pain management itself divides into cancer pain and chronic noncancer pain, with implant choice, opioid stewardship practices, and palliative care integration differing substantially between these populations. Spasticity management encompasses conditions such as cerebral palsy, multiple sclerosis, and spinal cord injury, each with distinct functional goals, multidisciplinary care needs, and long-term rehabilitation implications. Tailoring device features and service models to these clinical subpopulations enhances adherence and functional outcomes.

End-user dynamics are equally influential for deployment and service models. Based on end user, adoption pathways include ambulatory surgical centers, hospitals, and specialty clinics, each carrying different operational capabilities, reimbursement environments, and staffing models. Ambulatory surgical centers are increasingly attractive for elective implant procedures due to efficiency and patient preference, whereas hospitals often manage more medically complex cases and perioperative risks. Specialty clinics that provide longitudinal device programming and multidisciplinary follow-up are essential for maintaining therapy effectiveness and capturing outcomes data. Recognizing how these segmentation lenses intersect is critical for designing go-to-market approaches, clinician education programs, and long-term service offerings that align with real-world care delivery.

Key regional insights explaining how distinct regulatory, reimbursement, and infrastructure realities across the Americas, EMEA, and Asia-Pacific shape adoption and access strategies

Regional dynamics influence clinical adoption, regulatory engagement, and supply chain design across the intrathecal pump landscape. In the Americas, a dense network of academic centers and community hospitals has supported early adoption combined with robust post-approval clinical research. This region's reimbursement complexity and payer scrutiny influence how sponsors prioritize evidence generation, while consolidated hospital systems enable integrated care pathways that support long-term follow-up and device maintenance. Consequently, manufacturers often align market access strategies with health system evidence needs and value demonstration pilots.

Europe, the Middle East, and Africa present heterogeneous regulatory and reimbursement environments that compel flexible market-entry strategies. Western European countries generally emphasize comparative effectiveness and health technology assessment frameworks, prompting manufacturers to invest in real-world outcomes and cost-effectiveness studies. In contrast, parts of the Middle East and Africa may prioritize access and infrastructure development, creating opportunities for targeted capacity-building programs and local partnerships. Cross-border regulatory harmonization efforts and centralized procurement mechanisms in certain jurisdictions can accelerate technology adoption when evidence and service support are aligned.

Asia-Pacific exhibits a mix of mature markets with established regulatory pathways and emerging markets characterized by rapid investment in specialty care infrastructure. In advanced economies within the region, clinical innovators and private healthcare systems drive demand for high-performance devices and integrated service models. In emerging markets, demand is often shaped by investments in surgical capacity, changing disease burdens, and localized reimbursement decisions. Manufacturers seeking regional scale frequently adopt hybrid approaches that combine direct presence in mature markets with distributor partnerships and training programs in developing markets to ensure appropriate clinical adoption and continuity of care.

Across regions, common themes emerge: the necessity of local evidence generation, the importance of training clinical teams for implantation and follow-up, and the value of supply chain resilience. Tailoring commercial and clinical strategies to regional regulatory, payer, and infrastructural realities accelerates adoption while ensuring therapies remain accessible and clinically effective across diverse healthcare systems.

Key company-level insights showing how established manufacturers and innovative entrants compete through clinical evidence, service models, and software-enabled differentiation

Competitive dynamics in the intrathecal pump space reflect a balance between incumbent device reliability and the emergence of specialized innovators targeting niche clinical needs. Established manufacturers maintain advantages through long-term clinical data, extensive service networks, and integrated training programs that reduce implantation risk and support follow-up care. These capabilities foster institutional trust and simplify procurement decisions for hospitals and specialty clinics where clinical teams demand high reliability and robust post-market support.

At the same time, newer entrants and adjacent medical technology firms are differentiating through software-enabled features, remote monitoring, and modular design concepts that emphasize ease of programming and reduced maintenance burden. Such offerings appeal to health systems focused on outpatient care models and to specialists seeking finer titration capabilities. Collaboration between device developers and pharmaceutical sponsors has also intensified, particularly for drug-device combination strategies where co-development can streamline labeling and clinical trial design.

Service and commercial models are increasingly central to competitive positioning. Companies that offer comprehensive clinician training, local technical support, and transparent warranty and replacement policies create stickiness in clinical pathways. Additionally, vendors that invest in outcomes registries and real-world evidence initiatives build stronger value narratives with payers and health systems. Strategic partnerships with hospitals, academic centers, and rehabilitation networks further extend reach and support adoption by embedding devices within established care pathways.

For buyers and health system leaders, vendor selection now hinges on a broader set of criteria than device features alone. Total cost of therapy, service quality, evidence commitments, and the ability to collaborate on pathway redesign have become equally important. Consequently, suppliers that integrate clinical support, data services, and flexible commercial arrangements are better positioned to capture long-term partnerships and scale intrathecal therapy within complex care delivery ecosystems.

Actionable recommendations for device makers, clinicians, and payers to align evidence, digital capabilities, supply resilience, and commercial models for sustainable growth

Industry leaders must act decisively to align product roadmaps, clinical evidence generation, and supply chain resilience with evolving care delivery models. First, prioritize integrated value demonstrations that link device performance to clinically meaningful outcomes such as reduced systemic medication use, lower hospitalization rates, and improved functional status for spasticity patients. Engaging payers and large health systems early to design pragmatic evidence collection initiatives will shorten reimbursement deliberations and support value-based contracting pilots.

Second, invest in remote monitoring and telemetric capabilities that enable hybrid follow-up models and reduce the frequency of in-person visits without compromising safety. Remote data streams not only enhance patient convenience but also provide real-world endpoints that strengthen economic narratives. Complement these technical investments with clinician training programs that prepare broader surgical and specialty clinic networks to adopt implantation and programming protocols, which will expand suitable care settings beyond tertiary centers.

Third, build supply chain strategies that emphasize dual sourcing, localized manufacturing where feasible, and design-for-supply approaches that reduce dependence on tariff-exposed components. Strategic inventory management and supplier partnerships can buffer against short-term disruptions while preserving margins. Simultaneously, cultivate partnerships with rehabilitation and palliative care providers to embed intrathecal therapy within multidisciplinary care pathways, thereby improving patient identification and continuity of care.

Finally, structure commercial models around service and outcomes, not just hardware sales. Offer flexible contracting, warranty packages, and outcomes-based components where feasible to align incentives with purchasers. By integrating evidence generation, digital capabilities, and resilient operations into a coherent go-to-market strategy, industry leaders will be better equipped to scale therapies while addressing payer scrutiny and clinician expectations.

A transparent and rigorous research methodology combining clinician interviews, regulatory and literature review, supply chain analysis, and expert validation to ensure actionable insights

This research synthesizes multiple methodologies to ensure rigorous, reproducible insights. Primary research included structured interviews with implanting physicians, procurement leaders, and clinical program managers to capture operational realities, patient selection criteria, and follow-up workflows. These first-hand perspectives were complemented by clinician advisory panel discussions that validated clinical assumptions and highlighted practical barriers to scaling intrathecal therapies in diverse care settings.

Secondary research encompassed regulatory documentation, peer-reviewed clinical literature, and procedural best-practice guidelines to triangulate safety signals and device performance themes. Product technical specifications and service model descriptions were analyzed to identify emerging design trends and vendor capabilities. Additionally, analysis of clinical registry abstracts and published outcomes studies informed the synthesis of therapeutic and safety narratives specific to baclofen therapy, local anesthetic use, and opioid-based intrathecal interventions.

Supply chain and policy analysis drew on customs and trade publications, publicly available tariff schedules, and procurement case studies to assess the operational impact of 2025 tariff changes. Scenario analysis techniques were applied to evaluate plausible supply-side responses, including nearshoring, dual sourcing, and inventory strategies, and to understand their implications for manufacturers and healthcare providers. Throughout the study, findings were validated through cross-functional expert review to ensure practical relevance and factual accuracy.

The research approach prioritized transparency and reproducibility. Data gaps were documented and addressed through follow-up interviews or conservative interpretation, and limitations are clearly delineated to support appropriate application of insights. This methodological rigor ensures that conclusions are grounded in current clinical practice, regulatory realities, and operational constraints faced by stakeholders in the intrathecal pump ecosystem.

A concise conclusion highlighting the strategic imperatives for capturing clinical value, ensuring supply resilience, and aligning evidence with payer and provider needs

Intrathecal pump therapy stands at an inflection point where clinical promise, technological capability, and policy dynamics converge to create new opportunities and responsibilities for stakeholders. Advances in device design and telemetry are enabling safer, more patient-centric care models, while evolving payer expectations and regulatory attention demand stronger evidence and lifecycle stewardship. The 2025 tariff experience underscored the fragility of distributed supply chains and the strategic necessity of resilience planning to protect therapy continuity.

Segmentation across pump type, drug selection, therapy area, and end-user setting highlights that successful adoption depends on aligning product features with clinical workflows and support services. Regional differences in regulatory expectations and infrastructure further require tailored market approaches. Competitive differentiation is increasingly determined by the quality of service, evidence generation, and digital integration rather than hardware specifications alone.

Looking ahead, stakeholders that integrate robust real-world evidence programs, invest in remote monitoring, and fortify supply chain flexibility will be best positioned to expand access and demonstrate long-term value. Collaboration across manufacturers, clinical networks, and payers will accelerate adoption pathways and ensure that intrathecal therapies deliver meaningful outcomes for patients with complex pain and spasticity needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of MRI compatible intrathecal pumps for enhanced imaging safety
  • 5.2. Expansion of remote patient monitoring integration in intrathecal pump systems for real time therapy adjustments
  • 5.3. Growing emphasis on minimally invasive refill and programmable drug delivery intrathecal pump designs
  • 5.4. Increasing focus on opioid sparing pain management through targeted intrathecal drug delivery
  • 5.5. Regulatory approvals driving market uptake of next generation rechargeable intrathecal pump technologies
  • 5.6. Development of smart sensor enabled intrathecal pumps for automated dose control and complication detection
  • 5.7. Pressure on cost effectiveness and reimbursement policies shaping intrathecal pump adoption in hospitals
  • 5.8. Penetration of intrathecal pump therapy in emerging markets fueled by partnerships and local manufacturing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intrathecal Pumps Market, by Pump Type

  • 8.1. External Pumps
  • 8.2. Implantable Pumps

9. Intrathecal Pumps Market, by Drug Type

  • 9.1. Baclofen
  • 9.2. Local Anesthetics
  • 9.3. Opioids

10. Intrathecal Pumps Market, by Therapy Area

  • 10.1. Pain Management
    • 10.1.1. Cancer Pain
    • 10.1.2. Chronic Noncancer Pain
  • 10.2. Spasticity Management
    • 10.2.1. Cerebral Palsy
    • 10.2.2. Multiple Sclerosis
    • 10.2.3. Spinal Cord Injury

11. Intrathecal Pumps Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Intrathecal Pumps Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Intrathecal Pumps Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Intrathecal Pumps Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Flowonix Medical, Inc.
    • 15.3.3. Tricumed Medizintechnik GmbH
    • 15.3.4. Teleflex Inc.
    • 15.3.5. Johnson & Johnson Services Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INTRATHECAL PUMPS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INTRATHECAL PUMPS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTRATHECAL PUMPS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTRATHECAL PUMPS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTRATHECAL PUMPS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. GCC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GCC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GCC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. GCC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. GCC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. GCC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. GCC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 244. GCC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 245. GCC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 246. GCC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 247. GCC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 248. GCC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 249. GCC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. GCC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 276. BRICS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. G7 INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. G7 INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. G7 INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. G7 INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. G7 INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. G7 INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. G7 INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 286. G7 INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 287. G7 INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 288. G7 INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 289. G7 INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 290. G7 INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 291. G7 INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. G7 INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. NATO INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. NATO INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. NATO INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. NATO INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. NATO INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. NATO INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. NATO INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 300. NATO INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 301. NATO INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 302. NATO INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 303. NATO INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 304. NATO INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 305. NATO INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. NATO INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. CANADA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. CANADA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. CANADA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. CANADA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. CANADA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 326. CANADA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 327. CANADA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 328. CANADA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 329. CANADA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 330. CANADA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 331. CANADA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. CANADA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 338. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 339. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 340. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 341. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 342. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 343. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. BRAZIL INTRATHECAL PUMPS MARKET SIZE, BY PUMP T